Ofatumumab, a Second- Generation Anti-CD20 Monoclonal Antibody, For

Total Page:16

File Type:pdf, Size:1020Kb

Ofatumumab, a Second- Generation Anti-CD20 Monoclonal Antibody, For Drug Evaluation 1 2 Ofatumumab, a second- 3 4 generation anti-CD20 monoclonal 5 6 antibody, for the treatment 7 1. Introduction 8 of lymphoproliferative and 9 2. Synthesis 10 3. Preclinical development autoimmune disorders 11 4. Clinical development † 12 Jorge Castillo , Cannon Milani & Daniel Mendez-Allwood 5. Adverse events and † 13 Brown University Warren Alpert Medical School, The Miriam Hospital, Division of Hematology and contraindications 14 Oncology, Providence, RI, USA 15 6. Conclusions Background: Lymphoproliferative and autoimmune disorders share monoclonal 16 7. Expert opinion dysregulation and survival advantage of B-lymphocytes. Thus, therapies 17 18 directed towards eliminating B-cells will play an important role as CD20 is 19 exclusively expressed in B-lymphocytes and its modulation by monoclonal 20 antibodies such as rituximab has improved outcomes in lymphoproliferative 21 and autoimmune disorders. Ofatumumab is a new, fully human anti-CD20 22 antibody and has been shown to be effective and safe, but its role in these 23 conditions is still unclear. Objectives: To describe the preclinical and clinical 24 data available on ofatumumab for the treatment of lymphoproliferative 25 and autoimmune disorders. Methods: An extensive search of published 26 articles and abstracts on preclinical and clinical studies with ofatumumab 27 was undertaken. Conclusions: Ofatumumab is a second-generation anti- 28 CD20 antibody that has been demonstrated to be safe and efficacious in 29 patients with lymphoproliferative and autoimmune disorders. Ofatumumab 30 is fully human, attaches to a newly identified epitope and shows lower off- 31 rates and improved complement-dependent cytotoxicity. Initial data present 32 ofatumumab as an attractive agent with lower rates of infusion-related 33 events than rituximab. Ongoing Phase III trials in patients with follicular 34 lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis are 35 ongoing, and Phase II trials in patients with aggressive lymphoma and multiple 36 sclerosis are also under development. 37 38 Keywords: autoimmune disorders, CD20, chronic lymphocytic leukemia, lymphoma, monoclonal 39 antibody, multiple sclerosis, non-Hodgkin’s lymphoma, ofatumumab, rheumatoid arthritis 40 41 Expert Opin. Investig. Drugs (2009) 18(4):1-10 42 43 1. Introduction 44 45 B-lymphocytes play an important role in the development of lymphoproliferative 46 and autoimmune disorders (LPDs and AIDs, respectively). Briefly, LPDs are 47 characterized by a monoclonal proliferation of malignant B- or T-lymphocytes, in 48 which a combination of increased proliferation, survival advantage and/or 49 decreased apoptosis can be observed [1]. In a similar fashion, AIDs are character- 50 ized by B-lymphocyte dysregulation, which translates into increased activation 51 and development of uncontrolled self-recognition properties [2]. Furthermore, 52 there is a bidirectional association between these disorders, since patients with 53 LPDs often present with AIDs (e.g, lymphoma patients can develop autoimmune 54 hemolytic anemia) [3] and patients who suffer from AIDs have an increased risk 55 of developing LPDs (e.g., the risk of developing lymphoma in patients with 10.1517/13543780902832679 © 2009 Informa UK Ltd ISSN 1354-3784 1 All rights reserved: reproduction in whole or in part not permitted Ofatumumab 56 systemic lupus erythematosus is 7 times higher than in the anti-TNFα failure in 2006 based on a Phase III study 111 57 general population) [4]. Based on this evidence, drugs directed showing that the combination of rituximab and MTX 112 58 towards eliminating the malignant or autoimmune clones of improved responses in comparison to MTX alone based on 113 59 B-lymphocytes, such as anti-CD20 monoclonal antibodies, American College of Rheumatology (ACR) and European 114 60 can be of great therapeutic value in these disorders. League Against Rheumatism (EULAR) response criteria [17]. 115 61 Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic The dosing regimen for RA is different than those used to 116 62 leukemia (CLL) represent two distinct subcategories of treat lymphoma. For MS, multiple therapies are available, 117 63 malignant LPD, which originate from clonal proliferation of such as interferon, glatiramer acetate, mitoxantrone and natali- 118 64 malignant lymphocytes. NHL is the most predominant zumab, a humanized anti-CD74 MAb. The use of rituximab 119 65 adult hematologic malignancy in the USA with 66,000 in MS is limited to small trials but with hopeful results [18]. 120 66 anticipated cases in 2008 [5]; 85% of these cases will arise The premise of MAb activity centers upon modulating 121 67 from a malignant B-lymphocyte. The most common subtypes new functional receptors in malignant or autoimmune cells 122 68 are diffuse large B-cell (DLBCL) and follicular lymphoma to augment therapeutic efficacy. The actual mechanisms of 123 69 (FL). CLL, on the other hand, is the most prevalent LPD in action of MAb are unknown but, theoretically, their func- 124 70 the USA with 95,000 cases [6]. CLL is characterized by the tion is elicited by inducing complement-dependent cytotox- 125 71 accumulation of neoplastic CD5+/CD19+ B-lymphocytes. icity (CDC), antibody-dependent cellular cytotoxicity 126 72 Fifty per cent of cases will be largely asymptomatic and will (ADCC) and/or direct apoptosis [19]. Nonetheless, inherent 127 73 not need therapy. DLBCL is considered a curable disease; limitations arise with rituximab as resistance ensues in 128 74 but FL and CLL are incurable with current standard therapies. patients with low-grade NHL and CLL and responses are 129 75 AIDs comprise a constellation of conditions, such as rheu- less potent and shorter in duration [20,21]. Similarly, the effi- 130 76 matoid arthritis (RA) and multiple sclerosis (MS). RA has cacy of second-line therapy with rituximab is unclear in 131 77 an annual incidence of 30 cases per 100,000 population; DLBCL patients who failed rituximab as front-line ther- 132 78 more than a million Americans live with RA [7]. This condi- apy [10]. Moreover, rituximab has been linked to life-threat- 133 79 tion, which is characterized by the development of painful, ening infusion reactions, hepatitis B reactivation, tumor lysis 134 80 swollen joints and the presence of anticyclic citrullinated syndrome, severe mucocutaneous reactions and progressive 135 81 peptide antibodies, can be disabling and has a great impact multifocal encephalopathy [22,23]. Thus, it is paramount to 136 82 on quality of life and productivity as the joint damage discover and implement a new generation of MAb as a viable 137 83 becomes permanent with time, decreasing mobility. MS is treatment entity to achieve long-term remission while 138 84 the most common autoimmune demyelinating disease of the decreasing the rate of therapy-related adverse events. 139 85 central nervous system, affecting more than 300,000 people 140 86 in the USA [8]. It is twice as common in females as in 2. Synthesis 141 87 males, with a peak incidence at the age of 35 years but does 142 88 not affect lifespan substantially [9]. The most common form Ofatumumab (HuMax-CD20; GlaxoSmithKline, Collegeville, 143 89 of MS is relapsing-remitting MS (RRMS), characterized by PA, USA and Genmab, Copenhagen, Denmark) is an IgG1, 144 90 unpredictable relapses followed by either complete, partial fully human, second-generation anti-CD20 MAb with a 145 91 or no neurological recovery. molecular weight of approximately 150 kDa. Ofatumumab 146 92 In 1997, the advent of rituximab (Rituxan®, Genentech, was produced by immunizing HCo7 and KM mice with a 147 93 South San Francisco, CA, USA), a chimeric anti-CD20 murine cell line (NS/0) transfected with human heavy- and 148 94 monoclonal antibody (MAb), dramatically altered the foun- light-chain genes. The hybridoma was created by fusing 149 95 dation for the treatment of NHL. Rituximab is approved as B-cells from immunized mice and NS/0 cells. CD20-specific 150 96 both first-line treatment for aggressive and indolent subtypes IgG1-producing hybridomas were then sequenced and sub- 151 97 of NHL (DLBCL and FL, respectively), and for relapsed or cloned. Unique features to ofatumumab compared with 152 98 refractory, indolent or follicular, CD20-positive NHL. Clinical rituximab are a different binding site, prolonged release time 153 99 data reported by multiple investigators demonstrated from the target site and stronger CDC activity. Ofatumumab 154 100 increased response rates and prolonged survival times with is now under clinical development for indolent and aggressive 155 101 rituximab in combination with chemotherapy in patients NHL, CLL, RA and MS with promising results. 156 102 with DLBCL [10-12] and FL [13,14]. Similarly, the clinical 157 103 benefits of rituximab can be seen in patients with CLL 3. Preclinical development 158 104 when added to other chemotherapeutic agents or, to a lesser 159 105 degree, as single agent [15,16]. Of note, rituximab is not yet Elegant work from Teeling and colleagues [24] defined a series 160 106 approved by the FDA to treat CLL but it is the most com- of three fully human anti-CD20 MAbs (ofatumumab, 7B8 and 161 107 monly used MAb for this condition. The treatment for RA 11B8) with distinct characteristics. The first two were desig- 162 108 is based in nonspecific modulation of B-cells by corticoster- nated as type I anti-CD20 MAbs (rituximab-like), given their 163 109 oids, methotrexate (MTX) and anti-TNFα MAb. Rituximab ability of translocating and concentrating CD20 molecules 164 110 obtained FDA approval for the treatment of RA after into detergent-insoluble lipid rafts and inducing CDC. The 165 2 Expert Opin. Investig. Drugs (2009) 18(4) Castillo, Milani & Mendez-Allwood 166 MAb 11B8 was designated as type II (tositumomab-like) epitope to the cellular membrane plays a role in achieving 221 167 given its greater ability of eliciting ADCC and apoptosis. By stronger CDC activity.
Recommended publications
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • Primary Mediastinal Large B-Cell Lymphoma
    Primary Mediastinal Large B-Cell Lymphoma Page 1 of 13 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women. Note: Consider Clinical Trials as treatment options for eligible patients. PATHOLOGIC DIAGNOSIS INITIAL EVALUATION ESSENTIAL: 5 ● Physical exam: attention to node-bearing areas, including Waldeyer's ring, ESSENTIAL: and to size of liver and spleen ● ECOG performance status ● Hematopathology review of all slides with at least one paraffin ● B symptoms (Unexplained fever >38°C during the previous month; block or 15 unstained slides representative of the tumor. Rebiopsy if Recurrent drenching night sweats during the previous month; Weight consult material is nondiagnostic. loss >10 percent of body weight ≤ 6 months of diagnosis) ● Adequate morphology and immunophenotyping to establish 1 ● CBC with differential, LDH, BUN, creatinine, albumin, AST, diagnosis ALT, total bilirubin, alkaline phosphatase, serum calcium, uric acid ○ Paraffin Panel: CD3, CD20 and/or another pan-B-cell marker ● Beta 2 microglobulin (CD19, PAX-5, CD79a) or ● Screening for HIV 1 and 2, hepatitis B and C (HBcAb, HBsAg, HCV
    [Show full text]
  • Activity of Rituximab and Ofatumumab Against Mantle
    ACTIVITY OF RITUXIMAB AND OFATUMUMAB AGAINST MANTLE CELL LYMPHOMA(MCL) IN VITRO IN MCL CELL LINES BY COMPLEMENT DEPENDENT CYTOTOXICITY (CDC)AND ANTIBODY-DEPENDENT CELL MEDIATED CYTOTOXICITY ASSAYS(ADCC) Dr. Gopichand Pendurti M.B.B.S Mentor: Dr. Francisco J. Hernandez-Ilizaliturri MD Overview of presentation •Introduction to mantle cell lymphoma. •Concept of minimal residual disease. •Anti CD 20 antibodies. •51Cr release assays. •Flow cytometry on cell lines. •Results. •Future. MANTLE CELL LYMPHOMA •Mantle cell lymphoma is characterized by abnormal proliferation of mature B lymphocytes derived from naïve B cells. •Constitutes about 5% of all patients with Non Hodgkin's lymphoma. •Predominantly in males with M:F ratio 2.7:1 with onset at advanced age (median age 60yrs). •It is an aggressive lymphoma with median survival of patients being 3-4 years. •Often presents as stage III-IV with lymphadenopathy, hepatosplenomegaly, gastrointestinal involvement, peripheral blood involvement. Pedro Jares, Dolors Colomer and Elias Campo Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics Nature revision of cancer 2007 October:7(10):750-62 •Genetic hallmark is t(11:14)(q13:q32) translocation leading to over expression of cyclin D1 which has one of the important pathogenetic role in deregulating the cell cycle. •Other pathogentic mechanisms include molecular and chromosomal alterations that Target proteins that regulate the cell cycle and senecense (BMI1,INK4a,ARF,CDK4 AND RB1). Interfere with cellular
    [Show full text]
  • Refreshing the Biologic Pipeline 2020
    news feature Credit: Science Lab / Alamy Stock Photo Refreshing the biologic pipeline 2020 In the absence of face-to-face meetings, FDA and industry implemented regulatory workarounds to maintain drug and biologics approvals. These could be here to stay. John Hodgson OVID-19 might have been expected since 1996) — a small miracle in itself “COVID-19 confronted us with the need to severely impair drug approvals (Fig. 1 and Table 1). to better triage sponsors’ questions,” says Cin 2020. In the event, however, To the usual crop of rare disease and Peter Marks, the director of the Center for industry and regulators delivered a small genetic-niche cancer treatments, 2020 Biologics Evaluation and Research (CBER) miracle. They found workarounds and also added a chimeric antigen receptor at the FDA. “That was perhaps the single surrogate methods of engagement. Starting (CAR)-T cell therapy with a cleaner biggest takeaway from the pandemic related in January 2020, when the outbreak veered manufacturing process and the first to product applications.” Marks says that it westward, the number of face-to face approved blockbuster indication for a became very apparent with some COVID- meetings declined rapidly; by March, small-interfering RNA (siRNA) — the 19-related files that resolving a single they were replaced by Webex and Teams. European Medicines Agency’s (EMA) issue can help a sponsor enormously and (Secure Zoom meeting are to be added registration of the RNA interference accelerate the development cycle. Before this year.) And remarkably, by 31 December, (RNAi) therapy Leqvio (inclisiran) for COVID-19, it was conceivable that a small the US Food and Drug Administration cardiovascular disease.
    [Show full text]
  • Cancer Drug Shortages: Who's Minding the Store?
    ✽ ✽ [ News ✽ Analysis ✽ Commentary ✽ Controversy ] February 25, 2011 Vol. 33 No. 4 oncology-times.com Publishing for O33 Years NCOLOGY The Independent TIMES Hem/Onc News Source Cancer Drug Shortages: Who’s Minding the Store? he recent shortages of certain chemotherapy agents and other key drugs raise Tquestions about who’s in charge of the national drug supply and how to ensure availability when there are limited fi nancial incentives and no mandates that manu- facturers notify the FDA about upcoming shortages. Here’s what experts are saying. Page 25 iStockphoto.com/klenova ASCO: For Patients with Advanced Cancer, Start Frank Talks about Options Soon after Diagnosis p.22 iStockphoto.com ODAC Backs FDA on Post-Marketing Medical Home Concept Comes Studies for Accelerated-Approval to Oncology p.45 Drugs p.8 [ ALSO ] SHOP TALK . 4 JOE SIMONE: The Self-Referral Boom . .15 MIKKAEL SEKERES: On (cology) Language . .16 Colorectal Cancer: Best to Start Chemo by 4 Weeks After Surgery . 18 Breast Cancer: 4 Cycles of Adjuvant Chemo Usually Suffi cient . 36 WENDY HARPHAM: ‘It’s OK’. 40 POETRY BY CANCER CAREGIVERS . 47 Ph+ ALL: Early Use of Imatinib Extends Long-Term Survival. 49 Twitter.com/OncologyTimes PERIODICALS bitly.com/oncologytimes 9 oncology times Saturating Liver Cancers with Chemotherapy Found to Extend Survival & Decrease Toxicity athing liver tumors in chemo- The study included 93 patients: said Charles Nutting, DO, FSIR, an Btherapy increases survival, accord- 44 received PHP and 49 had interventional radiologist at Swedish ing to a Phase III trial reported at the standard treatment (typically systemic Medical Center in Denver.
    [Show full text]
  • Whither Radioimmunotherapy: to Be Or Not to Be? Damian J
    Published OnlineFirst April 20, 2017; DOI: 10.1158/0008-5472.CAN-16-2523 Cancer Perspective Research Whither Radioimmunotherapy: To Be or Not To Be? Damian J. Green1,2 and Oliver W. Press1,2,3 Abstract Therapy of cancer with radiolabeled monoclonal antibodies employing multistep "pretargeting" methods, particularly those has produced impressive results in preclinical experiments and in utilizing bispecific antibodies, have greatly enhanced the thera- clinical trials conducted in radiosensitive malignancies, particu- peutic efficacy of radioimmunotherapy and diminished its toxi- larly B-cell lymphomas. Two "first-generation," directly radiola- cities. The dramatically improved therapeutic index of bispecific beled anti-CD20 antibodies, 131iodine-tositumomab and 90yttri- antibody pretargeting appears to be sufficiently compelling to um-ibritumomab tiuxetan, were FDA-approved more than a justify human clinical trials and reinvigorate enthusiasm for decade ago but have been little utilized because of a variety of radioimmunotherapy in the treatment of malignancies, particu- medical, financial, and logistic obstacles. Newer technologies larly lymphomas. Cancer Res; 77(9); 1–6. Ó2017 AACR. "To be, or not to be, that is the question: Whether 'tis nobler in the pembrolizumab (anti-PD-1), which are not directly cytotoxic mind to suffer the slings and arrows of outrageous fortune, or to take for cancer cells but "release the brakes" on the immune system, arms against a sea of troubles, And by opposing end them." Hamlet. allowing cytotoxic T cells to be more effective at recognizing –William Shakespeare. and killing cancer cells. Outstanding results have already been demonstrated with checkpoint inhibiting antibodies even in far Introduction advanced refractory solid tumors including melanoma, lung cancer, Hodgkin lymphoma and are under study for a multi- Impact of monoclonal antibodies on the field of clinical tude of other malignancies (4–6).
    [Show full text]
  • B-Cell Targets to Treat Antibody-Mediated Rejection In
    Muro et al. Int J Transplant Res Med 2016, 2:023 Volume 2 | Issue 2 International Journal of Transplantation Research and Medicine Commentary: Open Access B-Cell Targets to Treat Antibody-Mediated Rejection in Transplantation Manuel Muro1*, Santiago Llorente2, Jose A Galian1, Francisco Boix1, Jorge Eguia1, Gema Gonzalez-Martinez1, Maria R Moya-Quiles1 and Alfredo Minguela1 1Immunology Service, University Clinic Hospital Virgen de la Arrixaca, Spain 2Nephrology Service, University Clinic Hospital Virgen de la Arrixaca, Spain *Corresponding author: Manuel Muro, PhD, Immunology Service, University Clinic Hospital “Virgen de la Arrixaca”, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain, Tel: 34-968-369599, E-mail: [email protected] Antibody-mediated rejection (AMR) in allograft transplantation APRIL (a proliferation-inducing ligand). These co-activation signals can be defined with a rapid increase in the levels of specific are required for B-cell differentiation into plasma cell and enhancing serological parameters after organ transplantation, presence of donor their posterior survival and are a key determinant of whether specific antibodies (DSAs) against human leukocyte antigen (HLA) developing B-cells will survive or die during the establishment molecules, blood group (ABO) antigens and/or endothelial cell of immuno-tolerance [5,6]. Important used agents commercially antigens (e.g. MICA, ECA, Vimentin, or ETAR) and also particular available are Tocilizumab (anti-IL6R) and Belimumab (BAFF). histological parameters [1,2]. If the AMR persists or progresses, the The receptors of BAFF and APRIL could also be important as treatment to eliminate the humoral component of acute rejection eventual targets, for example BAFF-R, TACI (transmembrane include three sequential steps: (a) steroid pulses, antibody removal activator and calcium modulator and cyclophyllin ligand interactor) (plasma exchange or immuno-adsorption) and high doses of and BCMA (B-cell maturation antigen).
    [Show full text]
  • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Non-Hodgkin’S Lymphomas Version 2.2015
    NCCN Guidelines Index NHL Table of Contents Discussion NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Non-Hodgkin’s Lymphomas Version 2.2015 NCCN.org Continue Version 2.2015, 03/03/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN® . Peripheral T-Cell Lymphomas NCCN Guidelines Version 2.2015 NCCN Guidelines Index NHL Table of Contents Peripheral T-Cell Lymphomas Discussion DIAGNOSIS SUBTYPES ESSENTIAL: · Review of all slides with at least one paraffin block representative of the tumor should be done by a hematopathologist with expertise in the diagnosis of PTCL. Rebiopsy if consult material is nondiagnostic. · An FNA alone is not sufficient for the initial diagnosis of peripheral T-cell lymphoma. Subtypes included: · Adequate immunophenotyping to establish diagnosisa,b · Peripheral T-cell lymphoma (PTCL), NOS > IHC panel: CD20, CD3, CD10, BCL6, Ki-67, CD5, CD30, CD2, · Angioimmunoblastic T-cell lymphoma (AITL)d See Workup CD4, CD8, CD7, CD56, CD57 CD21, CD23, EBER-ISH, ALK · Anaplastic large cell lymphoma (ALCL), ALK positive (TCEL-2) or · ALCL, ALK negative > Cell surface marker analysis by flow cytometry: · Enteropathy-associated T-cell lymphoma (EATL) kappa/lambda, CD45, CD3, CD5, CD19, CD10, CD20, CD30, CD4, CD8, CD7, CD2; TCRαβ; TCRγ Subtypesnot included: · Primary cutaneous ALCL USEFUL UNDER CERTAIN CIRCUMSTANCES: · All other T-cell lymphomas · Molecular analysis to detect: antigen receptor gene rearrangements; t(2;5) and variants · Additional immunohistochemical studies to establish Extranodal NK/T-cell lymphoma, nasal type (See NKTL-1) lymphoma subtype:βγ F1, TCR-C M1, CD279/PD1, CXCL-13 · Cytogenetics to establish clonality · Assessment of HTLV-1c serology in at-risk populations.
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with Zirconium 89 In
    Journal of Nuclear Medicine, published on January 18, 2018 as doi:10.2967/jnumed.117.203299 Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with Zirconium 89 in Human Lymphoma Xenografts Jason T. Yoon†,1, Mark S. Longtine†,1, Bernadette V. Marquez-Nostra1,2, and Richard L. Wahl1 †Contributed equally. 1Mallinckrodt Institute of Radiology, Washington University, St. Louis, MO 63110. 2Current address: Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University, PO Box 208048, New Haven, CT, 056520. First author (Jason Yoon) address: as noted above. Phone, 714-364-7560; E-mail, [email protected] For correspondence or reprints contact: Richard Wahl, MD Washington University School of Medicine, Department of Radiology, Campus Box 8131, 660 S. Euclid Ave, St. Louis, MO 63110 Telephone: (314) 362-7100, Fax: (314)747-4189 Email: [email protected] Financial Support: This study was funded, in part, by Radiological Society of North America Education and Research Foundation Medical Student research award, RMS1646, to JTY and RLW. BVMN is supported by the National Institutes of Health (grant 1K99CA201601). Word Count of Manuscript: 4,994 Running Title: Next-Generation 89Zr-Anti-CD20 mAbs ABSTRACT Radioimmunotherapies with monoclonal antibodies (mAbs) to the B-lymphocyte antigen 20 (CD20) are effective treatments for B-cell lymphomas, but United States Food and Drug Administration (FDA)-approved radioimmunotherapies exclusively use radiolabeled murine antibodies, potentially limiting re-dosing. The FDA recently approved two unlabeled anti-CD20 monoclonal antibodies, obinutizumab and ofatumumab, termed "next generation" as they are humanized (obinituzumab) or fully human (ofatumumab), thus potentially allowing a greater potential for re-dosing than with previous generation anti-CD20 antibodies, including rituximab (chimeric) and tositumumab (murine) which contain more murine peptide sequences.
    [Show full text]
  • Drug Resistance in Non-Hodgkin Lymphomas
    International Journal of Molecular Sciences Review Drug Resistance in Non-Hodgkin Lymphomas Pavel Klener 1,2,* and Magdalena Klanova 1,2 1 First Department of Internale Medicine-Hematology, University General Hospital in Prague, 128 08 Prague, Czech Republic; [email protected] 2 Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, 128 53 Prague, Czech Republic * Correspondence: [email protected] or [email protected] Received: 3 February 2020; Accepted: 15 March 2020; Published: 18 March 2020 Abstract: Non-Hodgkin lymphomas (NHL) are lymphoid tumors that arise by a complex process of malignant transformation of mature lymphocytes during various stages of differentiation. The WHO classification of NHL recognizes more than 90 nosological units with peculiar pathophysiology and prognosis. Since the end of the 20th century, our increasing knowledge of the molecular biology of lymphoma subtypes led to the identification of novel druggable targets and subsequent testing and clinical approval of novel anti-lymphoma agents, which translated into significant improvement of patients’ outcome. Despite immense progress, our effort to control or even eradicate malignant lymphoma clones has been frequently hampered by the development of drug resistance with ensuing unmet medical need to cope with relapsed or treatment-refractory disease. A better understanding of the molecular mechanisms that underlie inherent or acquired drug resistance might lead to the design of more effective front-line treatment algorithms based on reliable predictive markers or personalized salvage therapy, tailored to overcome resistant clones, by targeting weak spots of lymphoma cells resistant to previous line(s) of therapy. This review focuses on the history and recent advances in our understanding of molecular mechanisms of resistance to genotoxic and targeted agents used in clinical practice for the therapy of NHL.
    [Show full text]
  • Hodgkin's Lymphoma Unresponsive to Rituximab Or a Rituximab
    Clinical Development GSK1841157 Protocol OMB110918 / NCT01077518 A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non- Hodgkin’s Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment Authors Document type Amended Protocol Version EUDRACT number 2008-004177-17 Version number 11 Development phase III Document status Final Release date 13-Apr-2017 Novartis internal reference number COMB157E2301 Property of Novartis Confidential May not be used, divulged, published, or otherwise disclosed without the consent of Novartis Novartis Confidential Page 2 Amended Protocol Version 11 Clean Protocol No. COMB157E2301/OMB110918 Amendment 9 (13-Apr-2017) Amendment rationale The purpose of amendment 9 is to revise the total number of events required for the primary analysis of the primary end point PFS. The primary analysis was planned after reaching 259 PFS events as determined by an Independent Review Committee (IRC). Based on the current status of the study and PFS event count by IRC, it is highly unlikely that the 259 PFS events will be achieved. The study has been ongoing since September 2010 when the first patient was enrolled and the study sponsorship changed in February 2016 from GSK to Novartis (Amendment 8 , dated 18Mar2016). Per protocol, Interim Analysis for efficacy and futility and IDMC review occurred (22Feb2016) after 180 PFS events by IRC were reached (31Oct2015). IDMC recommended to continue the study without changes. The interim analysis of PFS was performed by an independent Statistical Data Analysis Centre. As per IDMC charter, unblinded results were not communicated to the sponsor in order to maintain the integrity of the trial.
    [Show full text]